Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation

Baigalmaa Lkhagva; Yu Hsun Kao; Yao Chang Chen; Tze Fan Chao; Shih Ann Chen; Yi Jen Chen

doi:10.1016/j.ejphar.2016.04.034

Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation

Baigalmaa Lkhagva, Yu Hsun Kao, Yao Chang Chen, Tze Fan Chao, Shih Ann Chen, Yi Jen Chen

Research output: Contribution to journal › Review article › peer-review

18 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is a common cardiac arrhythmia associated with high mortality and morbidity. Current treatments of AF have limited efficacy and considerable side effects. Histone deacetylases (HDACs) play critical roles in the pathophysiology of cardiovascular diseases and contribute to the genesis of AF. Therefore, HDAC inhibition may prove a novel therapeutic strategy for AF through upstream therapy and modifications of AF electrical and structural remodeling. In this review, we provide an update of the knowledge of the effects of HDACs and HDAC inhibitors on AF, and dissect potential underlying mechanisms.

Original language	English
Pages (from-to)	250-257
Number of pages	8
Journal	European Journal of Pharmacology
Volume	781
DOIs	https://doi.org/10.1016/j.ejphar.2016.04.034
Publication status	Published - 2016

Keywords

Atrial fibrillation
HDAC inhibitors
Histone deacetylases
Non-histone proteins

ASJC Scopus subject areas

Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejphar.2016.04.034

Cite this

@article{08823e658da945eda51f394cfc48f7b2,

title = "Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation",

abstract = "Atrial fibrillation (AF) is a common cardiac arrhythmia associated with high mortality and morbidity. Current treatments of AF have limited efficacy and considerable side effects. Histone deacetylases (HDACs) play critical roles in the pathophysiology of cardiovascular diseases and contribute to the genesis of AF. Therefore, HDAC inhibition may prove a novel therapeutic strategy for AF through upstream therapy and modifications of AF electrical and structural remodeling. In this review, we provide an update of the knowledge of the effects of HDACs and HDAC inhibitors on AF, and dissect potential underlying mechanisms.",

keywords = "Atrial fibrillation, HDAC inhibitors, Histone deacetylases, Non-histone proteins",

author = "Baigalmaa Lkhagva and Kao, {Yu Hsun} and Chen, {Yao Chang} and Chao, {Tze Fan} and Chen, {Shih Ann} and Chen, {Yi Jen}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier B.V.",

year = "2016",

doi = "10.1016/j.ejphar.2016.04.034",

language = "English",

volume = "781",

pages = "250--257",

journal = "European Journal of Pharmacology",

issn = "0014-2999",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Targeting histone deacetylases

T2 - A novel therapeutic strategy for atrial fibrillation

AU - Lkhagva, Baigalmaa

AU - Kao, Yu Hsun

AU - Chen, Yao Chang

AU - Chao, Tze Fan

AU - Chen, Shih Ann

AU - Chen, Yi Jen

PY - 2016

Y1 - 2016

N2 - Atrial fibrillation (AF) is a common cardiac arrhythmia associated with high mortality and morbidity. Current treatments of AF have limited efficacy and considerable side effects. Histone deacetylases (HDACs) play critical roles in the pathophysiology of cardiovascular diseases and contribute to the genesis of AF. Therefore, HDAC inhibition may prove a novel therapeutic strategy for AF through upstream therapy and modifications of AF electrical and structural remodeling. In this review, we provide an update of the knowledge of the effects of HDACs and HDAC inhibitors on AF, and dissect potential underlying mechanisms.

AB - Atrial fibrillation (AF) is a common cardiac arrhythmia associated with high mortality and morbidity. Current treatments of AF have limited efficacy and considerable side effects. Histone deacetylases (HDACs) play critical roles in the pathophysiology of cardiovascular diseases and contribute to the genesis of AF. Therefore, HDAC inhibition may prove a novel therapeutic strategy for AF through upstream therapy and modifications of AF electrical and structural remodeling. In this review, we provide an update of the knowledge of the effects of HDACs and HDAC inhibitors on AF, and dissect potential underlying mechanisms.

KW - Atrial fibrillation

KW - HDAC inhibitors

KW - Histone deacetylases

KW - Non-histone proteins

UR - http://www.scopus.com/inward/record.url?scp=84963979424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963979424&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2016.04.034

DO - 10.1016/j.ejphar.2016.04.034

M3 - Review article

C2 - 27089819

AN - SCOPUS:84963979424

SN - 0014-2999

VL - 781

SP - 250

EP - 257

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

ER -

Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this